Research presented at ECCMID examining influenza transmission has discovered that a substantial proportion of patients and healthcare workers shed the flu virus before clinical symptoms appear.
Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.
Maternal infections, including influenza, can lead to higher rates of adverse fetal outcomes. New research suggests high levels of choline during gestation could mitigate this impact.
The WHO has released a Global Influenza Strategy for 2019–2030 aiming to prevent seasonal flu, prepare for a pandemic situation and control the spread of zoonotic influenza.
To round up 2018, we asked our Expert panel to choose their top papers from across the year. Here, you can discover the articles they selected and read about and the reasons why!
Collaborative research efforts with scientists from Janssen, the Scripps Research Institute, the University of Hong Kong, the University of Pennsylvania and more has led to success in creating a promising novel long-lasting llama-derived antibody therapy for influenza.
Roche has announced the FDA approval of Xofluza™, the first and only single-dose oral medicine approved to treat flu.
New research indicates that false negative RIAT results could delay antiviral therapy for half of patients admitted to intensive care units.
A high-fiber diet can boost the immune response and increase survival in mice infected with influenza virus, according to new research.
Take a look at how advancements in genetic engineering has led to advances in vaccine manufacturing, with a divergence from live cell cultures to recombinant production in host cells.
